Table 7 Strong positive expresssion of p110 isforms and pAKT in 60 patients with DLBCLs by IHC
|  |  | p110α | P value | p110β | P value | p110δ | P value | p110γ | P value | pAKT | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total no. of patients | 60 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Age, years | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
<60 y | 36 | 12 (33.3) | 0.037 | 10 (27.8) | 0.639 | 12 (33.3) | 0.068 | 7 (19.4) | 1.000 | 7 (19) | 0.293 |
≥60 y | 24 | 4 (16.7) |  | 5 (20.8) |  | 3 (12.5) |  | 4 (16.7) |  | 2 (8.3) |  |
Sex | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Male | 39 | 7 (17.9) | 0.153 | 9 (23.1) | 0.762 | 11 (28.2) | 0.435 | 7 (17.9) | 1.000 | 7 (17.9) | 0.473 |
 Female | 21 | 9 (42.9) |  | 6 (28.6) |  | 4 (19.0) |  | 4 (19.0) |  | 2 (9.5) |  |
Primary site | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
 node | 54 | 14 (25.9) | 0.653 | 14 (25.9) | 1.000 | 14 (25.9) | 1.000 | 8 (14.8) | 0.069 | 8 (14.8) | 1.000 |
Perpheral node | 6 | 2 (33.3) | Â | 1 (26.7) | Â | 1 (16.7) | Â | 3 (50.0) | Â | 1 (16.6) | Â |
B symptoms | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
 Absence | 37 | 10 (27.0) | 0.936 | 10 (27.0) | 0.764 | 11 (29.7) | 0.283 | 6 (16.2) | 0.734 | 4 (10.8) | 0.284 |
 Presence | 23 | 6 (26.1) |  | 5 (21.7) |  | 4 (17.4) |  | 5 (21.7) |  | 5 (21.7) |  |
Bulky disease | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
<10 cm | 47 | 11 (23.4) | 1.000 | 13 (27.7) | 0.561 | 12 (25.5) | 1.000 | 8 (17.0) | 0.552 | 7 (14.9) | 1.000 |
≥10 cm | 4 | 1 (25.0) |  | 1 (0) |  | 1 (25.0) |  | 1 (25.0) |  | 0 (0) |  |
Performance status | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
 ECOG 0-1 | 50 | 13 (26.0) | 1.000 | 13 (26.0) | 0.965 | 12 (24.0) | 1.000 | 9 (18.0) | 0.571 | 8 (16) | 1.000 |
 ECOG 2-4 | 4 | 1 (25.0) |  | 1 (25.0) |  | 1 (25.0) |  | 1 (25.0) |  | 0 (0) |  |
LDH | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
<2*insitutioal ULN | 30 | 9 (30.0) | 0.445 | 11 (36.7) | 0.133 | 9 (30.0) | 0.445 | 7 (23.3) | 0.483 | 6 (20) | 0.277 |
>2*insitutioal ULN | 24 | 5 (20.8) | Â | 4 (16.7) | Â | 5 (20.8) | Â | 3 (12.5) | Â | 2 (8.3) | Â |
Extranodal site | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
≤1 | 50 | 13 (26.0) | 1.000 | 14 (28.0) | 1.000 | 13 (26.0) | 1.000 | 9 (18.0) | 0.571 | 8 (16) | 1.000 |
>1 | 4 | 1 (25.0) | Â | 1 (25.0) | Â | 1 (25.0) | Â | 1 (25.0) | Â | 0 (0) | Â |
Stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
I/II | 29 | 5 (17.2) | 0.077 | 8 (27.6) | 0.904 | 10 (34.5) | 0.168 | 4 (13.8) | 0.307 | 4 (13.8) | 1.000 |
III/IV | 23 | 9 (39.1) | Â | 6 (26.1) | Â | 4 (17.4) | Â | 6 (26.1) | Â | 4 (17.4) | Â |
IPI | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 0-1 | 30 | 10 (33.3) | 0.142 | 11 (36.7) | 0.087 | 11 (36.7) | 0.037 | 5 (16.7) | 1.000 | 6 (20) | 0.269 |
 2-5 | 25 | 4 (16.0) |  | 4 (16.0) |  | 3 (12.0) |  | 5 (20.0) |  | 2 (8) |  |
Pathological type | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
 GCB | 26 | 4 (15.4) | 0.084 | 6 (23.1) | 0.764 | 4 (15.4) | 0.133 | 3 (11.5) | 0.320 | 4 (15.4) | 1.000 |
 non-GCB | 34 | 12 (35.3) |  | 9 (26.5) |  | 11 (32.4) |  | 8 (23.5) |  | 5 (14.7) |  |